Oral colon targeted delivery systems for treatment of inflammatory bowel diseases: Synthesis, in vitro and in vivo assessment

International Journal of Pharmaceutics

Volumn 358, Issue 1-2, 2008, Pages 248-255

  El Kamel, Amal H ^a   Abdel Aziz, Alaa A M ^a   Fatani, Amal J ^a   El Subbagh, Hussein I ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Aspartic acid; Colon; Cyclodextrin; In vivo in vitro; NSAIDs; Prodrug; Synthesis

Indexed keywords

2 [2 (2 FLUOROBIPHENYL 4 YL)PROPIONYLAMINO]SUCCINIC ACID; 2 [2 (6 METHOXYNAPHTHALEN 2 YL)PROPIONYLAMINO]SUCCINIC ACID; 2 [2 [6 FLUORO 3 (4 METHANESULFINYLBENZYLIDENE) 2 METHYL 3H INDEN 1 YL]ACETYL AMINO]SUCCINIC ACID; ACETIC ACID; ALPHA CYCLODEXTRIN DERIVATIVE; ASPARTIC ACID; BETA CYCLODEXTRIN DERIVATIVE; BETA CYCLODEXTRIN FLURBIPROFEN; BUFFER; CARBOXYL GROUP; CLINDAMYCIN; FLURBIPROFEN; GLUTATHIONE; HYDROXYL GROUP; NAPROXEN; SUCCINIC ACID DERIVATIVE; SULINDAC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON INJURY; CONTROLLED STUDY; DIGESTIVE SYSTEM INFLAMMATION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG HYDROLYSIS; DRUG RELEASE; DRUG SYNTHESIS; ENTERITIS; GASTROINTESTINAL TRACT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PH; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; STOMACH CONTENT; TISSUE HOMOGENATE;

ACETIC ACID; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPARTIC ACID; BUFFERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLON; CYCLODEXTRINS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FLURBIPROFEN; GASTROINTESTINAL TRANSIT; HYDROGEN-ION CONCENTRATION; HYDROLYSIS; INFLAMMATORY BOWEL DISEASES; MALE; NAPROXEN; PRODRUGS; RATS; SULINDAC;

EID: 44449117328     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.04.021     Document Type: Article

References (27)

1. Anekant J., Yashwant G., and Sanjay K.J. Perspectives of biodegradable natural polysaccharides for site-specific drug delivery to the colon. J. Pharm. Pharmaceut. Sci. 10 (2007) 86-128
2. Chourasia M.K., and Jain S.K. Polysaccharides for colon targeted drug delivery. Drug Deliv. 11 (2004) 129-148
3. El-Medany A., Mahgoub A., Mustafa A., Arafa M., and Morsic M. The effects of selective cyclooxygenase-2 inhibitors, celecoxib and rofecoxib, on experimental colitis induced by acetic acid in rats. Eur. J. Pharmacol. 507 (2005) 291-299
4. Flourie B., Molis C., Achour L., Dupas H., Hatat C., and Rambaud J.C. Fate of β-cyclodextrins in the human intestine. J. Nutr. 123 (1993) 676-680
5. Friend D.R. New oral delivery systems for treatment of inflammatory bowel disease. Adv. Drug Deliv. Rev. 57 (2005) 247-265
6. 14C-β-cylodextrin in rat. Arzneim. Forsch. Drug. Res. 35 (1985) 1042-1047
7. Guay D. Update on clindamycin in the management of bacterial, fungal and protozoal infections. Expert Opin. Pharmacother. 8 (2007) 2401-2444
8. Hirayama H., and Uekama K. Cyclodextrin-based controlled drug release systems. Adv. Drug Deliv. Rev. 36 (1999) 125-141
9. Ibekwe, V.C., Kendall, R.A., Basit, A.W., 2004. Drug delivery to the colon. Drug Delivery Companies Report Spring/Summer, pp. 27-30.
10. Jung Y.J., Lee J.S., and Kim Y.M. Colon-specific prodrugs of 5-aminosalicylic acid: synthesis and in vitro/in vivo properties of acidic amino acid derivatives of 5-aminosalicylic acid. J. Pharm. Sci. 90 (2001) 1767-1775
11. Jung B., Barbier V., Brickner H., Welsh J., Fotedar A., and McClelland M. Mechanisms of sulindac-induced apoptosis and cell cycle arrest. Cancer Lett. 219 (2005) 15-25
12. Kamada M., Hirayama F., Udo K., Yano H., Arima H., and Uekama K. Cyclodextrin conjugate-based controlled release system: repeated-and prolonged-releases of ketoprofen after oral administration in rats. J. Control. Release 82 (2002) 407-416
13. Koch T.R., Yuan L.X., Stryker S.J., Ratliff P., Telford G.L., and Opara E.C. Total antioxidant capacity of colon in patients with chronic ulcerative colitis. Dig. Dis. Sci. 45 (2000) 1814-1819
14. Millar A.D., Rampton D.S., Chander C.L., Claxson A.W.D., Blades S., Coumbe A., Panetta J., Morris C.J., and Blake D.R. Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis. Gut 39 (1996) 407-415
15. Minami K., Hirayama F., and Uekama K. Colon-specific drug delivery based on a cyclodextrin prodrug: release behavior of biphenylylacetic acid from its cyclodextrin conjugates in rat intestinal tracts after oral administration. J. Pharm. Sci. 87 (1998) 715-720
16. Myers C., Koki A., Pamukcu R., Wechter W., and Padley R.J. Proapoptotic anti-inflammatory drugs. Urology 57 (2001) 73-76
17. Nakamura J., Kido M., Nishida K., and Sasaki H. Effect of oral pretreatment with antibiotics on the hydrolysis of salicylic acid polysactyrosine and salicylic acid methionine prodrugs in rabbit intestinal microorganisms. Chem. Pharm. Bull. 40 (1992) 2572-2576
18. Owens C.W.J., and Belcher R.V. A colorimetric micromethod for determination of glutathione. Biochem. J. 94 (1965) 705-711
19. Rozou S., and Antoniadou-Vyza E. Chromatographic behaviour of naproxen-cyclodextrin complexes stationary phase C8 alkyl chain as competitor for the drug release from cyclodextrin cavity. J. Chromatogr. A 1041 (2004) 187-193
20. Ruan E.A., Rao S., Burdick J.S., Stryker S.J., Telford G.L., Otterson M.F., Opara E.C., and Koch T.R. Glutathione in the idiopathic inflammatory bowel diseases: relationship between colonic glutathione levels and inflammation. Nutr. Res. 17 (1997) 463-473
21. Sajeev C., Jadhav P.R., RaviShankar D., and Saha R.N. Determination of flurbiprofen in pharmaceutical formulations by UV spectrophotometry and liquid chromatography. Anal. Chim. Acta 463 (2002) 207-217
22. Sinha V.R., and Kumria R. Colonic drug delivery: prodrug approach. Pharm. Res. 18 (2001) 557-564
23. Sinha V.R., and Kumria R. Microbially triggered drug delivery to the colon. Eur. J. Pharm. Sci. 18 (2003) 3-18
24. Swanson B., and Boppana V.K. Measurement of sulindac and its metabolites in human plasma and urine by high-performance liquid chromatography. J. Chromatogr. Biomed. Appl. 225 (1981) 123-130
25. A [[(4-biphenylyl) acetyl]amino]-α-, β- and γ-cyclodextrins: potential prodrugs for colon-specific delivery. J. Med. Chem. 40 (1997) 2755-2761
26. Yamazaki R., Kusunoki N., Matsuzaki T., Hashimoto S., and Kawai S. Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett. 531 (2002) 278-284
27. Zou M., Cheng G., Okamoto H., Hao X., An F., Cui F., and Danjo K. Colon-specific drug delivery systems based on cyclodextrin prodrugs: in vivo evaluation of 5-amino salicylic acid from its cyclodextrin conjugates. World J. Gastroenterol. 11 (2005) 7457-7460